Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study.
Wang F, Numata K, Komiyama S, Miwa H, Sugimori K, Ogushi K, Moriya S, Nozaki A, Chuma M, Ruan L, Maeda S. Wang F, et al. Among authors: ogushi k. Front Oncol. 2022 May 4;12:843680. doi: 10.3389/fonc.2022.843680. eCollection 2022. Front Oncol. 2022. PMID: 35600400 Free PMC article.
Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma.
Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Tanaka K, Maeda S, Sakamoto N. Chuma M, et al. Among authors: ogushi k. Hepatol Res. 2019 Jul;49(7):810-822. doi: 10.1111/hepr.13338. Epub 2019 May 23. Hepatol Res. 2019. PMID: 30920086
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.
Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Chuma M, et al. Among authors: ogushi k. Cancers (Basel). 2020 Jan 26;12(2):293. doi: 10.3390/cancers12020293. Cancers (Basel). 2020. PMID: 31991869 Free PMC article.
Use of intra-procedural fusion imaging combining contrast-enhanced ultrasound using a perflubutane-based contrast agent and auto sweep three-dimensional ultrasound for guiding radiofrequency ablation and evaluating its efficacy in patients with hepatocellular carcinoma.
Sanga K, Numata K, Nihonmatsu H, Ogushi K, Fukuda H, Chuma M, Hashimoto H, Koizumi N, Maeda S. Sanga K, et al. Among authors: ogushi k. Int J Hyperthermia. 2020;37(1):202-211. doi: 10.1080/02656736.2020.1729422. Int J Hyperthermia. 2020. PMID: 32070164 Free article.
Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation.
Wang F, Numata K, Nihonmatsu H, Chuma M, Moriya S, Nozaki A, Ogushi K, Fukuda H, Ruan L, Okada M, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. Wang F, et al. Among authors: ogushi k. Int J Hyperthermia. 2020;37(1):1149-1158. doi: 10.1080/02656736.2020.1825837. Int J Hyperthermia. 2020. PMID: 32996799 Free article.
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.
Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Ogushi K, et al. Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020. Clin Exp Gastroenterol. 2020. PMID: 33061517 Free PMC article.
The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma.
Wang F, Numata K, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Fukuda H, Okada M, Ruan L, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. Wang F, et al. Among authors: ogushi k. Abdom Radiol (NY). 2021 Jun;46(6):2527-2539. doi: 10.1007/s00261-020-02881-0. Epub 2021 Jan 3. Abdom Radiol (NY). 2021. PMID: 33388895
42 results